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LETTERS TO THE EDITOR
Do Sulfonylurea Drugs Limit Coronary
Vasodilator Reserve?
The interesting observations published by Yokoyama et al. (1) in the
Journal raise a question in regard to one of their conclusions. They
measured myocardial flow reserve in response to dipyridamole in
diabetic patients and control subjects. Some of their patients were
taking oral hypoglycemic agents. One of their conclusions was that
myocardial flow reserve in the diet therapy group was comparable to
that in the medical therapy group. However, in the methods section, it
clearly states that no drugs were administered within 24 h before
cardiac catheterization. It seems likely then that the plasma levels of
oral hypoglycemic agents at the time of study were quite low and not
in the therapeutic range. Therefore, I wonder if their study truly
addresses the question of whether of sulfonylurea drugs impede
coronary vascular reserve. This question, as well as the affect of these
agents experimentally to prevent preconditioning, raises important
unanswered questions regarding their use in non–insulin-dependent
diabetes (2). The conclusion that sulfonylurea drugs do not further
alter myocardial flow reserve in diabetic patients unfortunately may
not be adequately addressed by Yokoyama et al. (1).
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Reply
We thank Engler for the important comment on our report. As stated
in our study (1), the effect of sulfonylurea on increased coronary
resistance and an attenuated response to reactive hyperemia with oral
hypoglycemic agents have been implicated (2–4). Those circumstances
may influence myocardial flow reserve (MFR) in patients with non–
insulin-dependent diabetes mellitus (NIDDM) who are receiving
sulfonylurea drugs. However, no significant difference in MFR was
observed between patients with NIDDM receiving diet therapy and
those receiving medical therapy in our study. As Engler states, the
blood concentration of sulfonylurea may be lowered in our patients
because the drugs were not administered within 24 h before the study.
Therefore, it is correct that an acute effect of sulfonylurea on MFR or
coronary preconditioning as previously reported (5) was not proved in
our study. However, MFR was apparently correlated with chronic
hyperglycemia in patients with NIDDM in our study. As mentioned,
there was no significant difference in MFR between patients with
NIDDM receiving diet therapy and those receiving medical therapy;
thus, long-term use of sulfonylurea might not alter MFR in patients
with NIDDM. Because NIDDM is a chronic disease and is not curable,
the duration of the disease state is long, and such lengthy periods may
be a factor in the vascular complications of this disease. Therefore, the
long-term effect of sulfonylurea on MFR is thought to be a much more
important matter than the short-term effect of such drugs in NIDDM.
As a result of our study, the effect of long-term usage of sulfonylurea
on MFR in NIDDM was not implicated. This result is an important
point for the long-term management of NIDDM with sulfonylurea.
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Role (of Assessment) of the Human
Collateral Circulation in (Characterizing)
Ischemic Adaptation to Repeated
Coronary Occlusion
Although the question asked by the study by Sakata et al. (1) in a
recent issue of the Journal is interesting, the methodology used to
reach the conclusion is disputable. The question asked was, “What is
the interaction between ischemic preconditioning (IP) and collateral
recruitment (CR) during ischemic adaptation (i.e., development of
ischemic tolerance, IT) in patients?”. That is, the contribution of each
of the terms IP and CR to the following equation was thought to be
tested:
IT 5 IP 1 CR.
A group of patients with visible collateral channels during coronary
angioplasty (group C) and one without (group N) according to
myocardial contrast echocardiography (MCE) were compared with
regard to their electrocardiographic (ECG) ST segment changes
during repeated occlusions. In group N, ST segment elevations during
angioplasty were pronounced, and their decrease during repeated
occlusions was significant (“suggesting the occurrence of IP”), whereas
both were practically absent in group C. The authors concluded that
“both ischemic preconditioning and collateral recruitment may play
independent roles in ischemic adaptation in humans.” An alternative
conclusion of the study results could be that MCE is able to distinguish
between patients with well and poorly developed collateral channels,
but since MCE was not used identically to the ECG (i.e., after each
occlusion), nothing can be said about the contribution of CR and IP to
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